Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia

NCT00002818 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT00002818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1
Overall status
Completed
Start date
February 28, 1995
Completion date
February 28, 2001
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug/agent toxicity by tissue/organ, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm